Showing results (401-410 of 420) with videos related to

Sort By:
Pageof 42
Blood|December 23, 1999
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndromeM S Tallman, J W Andersen, C A Schiffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II studyD R Parkinson, J S Abrams, P H Wiernik, et al.
Medical and Pediatric Oncology|January 1, 1979
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemiaP H Wiernik, O J Glidewell, H C Hoagland, et al.
The American Journal of Medicine|July 1, 1982
Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacinC A De Jongh, J C Wade, S C Schimpff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 1990
Hypersensitivity reactions from taxolR B Weiss, R C Donehower, P H Wiernik, et al.
Blood|August 15, 1997
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular studyR E Gallagher, C L Willman, J L Slack, et al.
The New England Journal of Medicine|December 3, 1998
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remissionP A Cassileth, D P Harrington, F R Appelbaum, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)R Advani, G Visani, D Milligan, et al.
Leukemia Research|August 24, 1999
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remissionR P Gale, R E Park, R W Dubois, et al.
Pageof 42